Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Axio BioPharma Partners with eMBR Genomics to Manufacture and Distribute Proprietary MKLP1 Pro™ Antibodies

In a milestone for cellular research, eMBR Genomics and Axio BioPharma announce the first commercial availability of MKLP1 Pro™ antibodies, KIF23 gene – the same tools used by the world's leading Midbody Remnants (MBRs) researchers. This strategic...

"Fresenius Kabi expands its U.S. pharma portfolio with the launch of Epinephrine Injection, USP

Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the United States as the first generic version of Epinephrine in a 1mg/1mL vial for U.S. customers. Epinephrine Injection, USP is a...

Isotopia collaborates with LIVEKIDNEY.BIO, marking a breakthrough in lupus treatment advancements

Isotopia is proud to announce a groundbreaking partnership with LIVEKIDNEY.BIO, a clinical-stage biotech innovator, to support the development of a critical component for its revolutionary lupus nephritis therapy. This collaboration offers the...

MM+M honors Petauri's Nicole Lodowski as a 2025 40 Under 40 awardee

Petauri, a leading purpose-built pharmaceutical services platform, announced that Nicole Lodowski, Managing Director of Petauri Evidence, has been recognized as one of MM+M's esteemed 40 Under 40 honorees for 2025. Amanda Peterson, Vice President...

Pilatus Biosciences Inc. earns FDA Orphan Drug Designation for PLT012, targeting liver and intrahepatic bile duct cancer

Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and intrahepatic bile duct cancer (HCC/ICCA). Achieved in November...

Biolexis Therapeutics reports positive outcomes for BLX-7006 in an expanded Diet-Induced Obesity (DIO) model study

Biolexis Therapeutics, a leading metabolic drug discovery company focused on improving the lives of patients with chronic metabolic conditions, including obesity, diabetes, and related diseases, announced the successful completion of an expanded...

SciTech Development reveals promising Phase 1A trial results for T-cell non-Hodgkin lymphoma therapy

SciTech Development, a clinical-stage pharmaceutical company focused on advancements in cancer treatment, is excited to share promising updates from its clinical trial of ST-001 nanoFenretinide (ST-001). Preliminary Trial Findings: Preliminary...

Dr. Jonathan Sadeh, ex-SVP of Immunology R&D at Bristol-Myers Squibb, joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Immunotherapeutics Ltd. a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that Dr. Jonathan Sadeh has...

NS Pharma announces a leadership change, appointing new commercial head to drive strategic growth and innovation

NS Pharma, Inc. announced a change of leadership within its Commercial division. Effective September 9, 2024, Donald Foy – who had previously served as national sales director – was appointed to the role of vice president, Commercial. Jennifer...

Pharmaceutics and Drug Delivery Systems 2024

Genvio Group is pleased to announce the “International conference on Pharmaceutics and Drug Delivery Systems” to be held on Nov 26-27, 2024 at Dubai, UAE. Genvio Group is pleased to announce the “International conference on Pharmaceutics and Drug...

Hanmi Pharmaceutical and Beijing Hanmi advance clinical trials for BH3120, their co-developed next-generation cancer immunotherapy

The latest progress in the clinical trial of BH3120, an innovative immunotherapy jointly developed by Hanmi Pharmaceutical and Beijing Hanmi Pharmaceutical, was recently presented at a major global academic conference, drawing significant...

Preclinical study shows NUZ-001 reduces TDP-43 aggregation in ALS

Neurizon Therapeutics Limited a clinical-stage biotech company advancing treatments for neurodegenerative diseases, is pleased to announce positive results from a preclinical study of its lead candidate, NUZ-001. These innovative studies reveal...

GenScript's ProBio subsidiary plays a key role in cutting-edge cancer therapies

GenScript Biotech, a global biotechnology leader in the life science, biologics manufacturing, synthetic biology, and cell therapies announced today that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova...

Axonal.AI launches an industry-first platform to accelerate life sciences time to market

Axonal.AI today unveiled its groundbreaking platform, designed to significantly accelerate speed to market in the life sciences industry. At a time when rapid commercialization is more critical than ever, Axonal.AI's cutting-edge technology...

Orsini begins distribution of CASGEVY® (exagamglogene autotemcel), a gene-editing therapy

Orsini has been chosen by Vertex Pharmaceuticals Incorporated to dispense gene-editing therapy CASGEVY® (exagamglogene autotemcel). CASGEVY is a CRISPR/Cas9 gene-edited cell therapy indicated for the treatment of patients aged 12 years and older...

ResQ Pharma receives PDUFA date for LipidRescue™, potentially the first FDA-approved treatment for Local Anesthetic Systemic Toxicity (LAST)

ResQ Pharma, Inc., a Chicago-based pharmaceutical company developing and commercializing innovative drug therapies, today announced that it has received a PDUFA (Prescription Drug User Fee Act) date of June 2, 2025, for its LipidRescue Kit. If...

SystImmune secures FDA clearance for BL-M17D1 IND in advanced solid tumors

SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for BL-M17D1, an antibody-drug conjugate (ADC) with a novel...

Transposon to share Phase 2 results of TPN-101 for C9orf72-related ALS/FTD at ALS ONE Research Symposium.

Transposon Therapeutics, a biotechnology company developing a platform of novel, orally administered therapies for the treatment of neurodegenerative and aging-related diseases, including Alzheimer's disease, announced that results from its Phase...

HanAll Biopharma releases Q3 2024 financial results and shares business updates

HanAll Biopharma Co., Ltd. a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, reported financial results for the third quarter of 2024 and provided business updates. HanAll ended the third...

GoodRx debuts a new e-commerce platform, starting with Opill®

GoodRx the leading prescription savings platform in the U.S., announced the rollout of its new e-commerce solution, with Opill® as its launch partner. This new seamless direct-to-consumer shopping experience allows consumers to order eligible...